Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495007 | 1.00 | P2RX7 (0.47) | P2RX7EHMT2MEN1KMT2ACYP2C19 | |
| SCHEMBL12018713 | 0.85 | P2RX7 (0.46) | P2RX7EHMT2MEN1KMT2ACYP2C19 | |
| SCHEMBL6133023 | 0.85 | P2RX7 (0.45) | P2RX7EHMT2MEN1KMT2ATSHR | |
| SCHEMBL6133226 | 0.85 | P2RX7 (0.45) | P2RX7EHMT2MEN1KMT2ATSHR | |
| SCHEMBL6132818 | 0.82 | P2RX7 (0.43) | P2RX7EHMT2MEN1KMT2AAGTR2 | |
| SCHEMBL27278853 | 0.81 | EHMT2 (0.49) | EHMT2MEN1KMT2ACYP2C19CYP3A4 | |
| SCHEMBL11065983 | 0.81 | EHMT2 (0.49) | EHMT2MEN1KMT2ACYP2C19CYP3A4 | |
| SCHEMBL20637914 | 0.81 | P2RX7 (0.44) | P2RX7EHMT2MEN1KMT2ATSHR | |
| SCHEMBL12018716 | 0.81 | P2RX7 (0.44) | P2RX7EHMT2MEN1KMT2ATSHR | |
| SCHEMBL1190522 | 0.79 | P2RX7 (0.58) | P2RX7EHMT2MEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466884-A | Heterocyclic compounds or salts thereof as ATR kinase inhibitors, pharmaceutical compositions containing same and uses thereof | 德州大学系统董事会 | 2024-01-30 | — | — | CN | disclosed |
| EP-3651768-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-111867590-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2023-11-17 | — | — | CN | disclosed |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| CN-111867590-A | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2020-10-30 | — | — | CN | disclosed |
| US-10800769-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800769-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | SHANGPHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| WO-2019014618-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011156610-A2 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | MAPT, PRNP, PSEN1 | P2RX7 2862/4885EHMT2 3102/4885MEN1 1876/4885 |
| US-10800769-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | P2RX7 4528/4885EHMT2 2189/4885MEN1 2344/4885 |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, EIF2AK2 | P2RX7 3918/4885EHMT2 4566/4885MEN1 4882/4885 |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | P2RX7 4528/4885EHMT2 2189/4885MEN1 2344/4885 |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | P2RX7 4528/4885EHMT2 2189/4885MEN1 2344/4885 |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | P2RX7 4528/4885EHMT2 2189/4885MEN1 2344/4885 |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | P2RX7 4528/4885EHMT2 2189/4885MEN1 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.